Determination of the Pharmacokinetics and Tissue Distribution of Methyl 3,4-Dihydroxybenzoate (MDHB) in Mice Using Liquid Chromatography-Tandem Mass Spectrometry
Background and Objectives
Methyl 3,4-dihydroxybenzoate (MDHB) has the potential to prevent neurodegenerative diseases (NDDs). The present work aims to reveal the pharmacokinetics and tissue distribution characteristics of MDHB.
The pharmacokinetics and tissue distribution of MDHB were analyzed using LC-MS/MS after a single intragastric administration (50 to 450 mg/kg) in mice, and samples were collected from five animals at specific time points.
Pharmacokinetic parameters of MDHB following intragastric administrations were: the time to peak concentration (Tmax) ranged from 0.033 to 0.07 h, the peak concentration (Cmax) ranged from 12,379.158 to 109798.712 μg/l, the elimination half-life (t1/2z) ranged from 0.153 to 1.291 h, the area under the curve (AUC0–∞) ranged from 640.654 to 20,241.081 μg/l × h, the mean residence time (MRT0–∞) ranged from 0.071 to 0.206 h, the apparent volume of distribution (Vz/F) ranged from 17.538 to 45.244 l/kg, and the systemic clearance (Clz/F) ranged from 22.541 to 80.807 l/h/kg. The oral bioavailability of MDHB was 23%. The maximum MDHB content was detected in the stomach, and the minimum content was observed in the testes; the peak content in the brain was 15,666.93 ng/g.
The pharmacokinetic characteristics of MDHB include fast absorption, high systemic clearance, a short half-life and an oral bioavailability of 23%. Additionally, MDHB permeates the blood-brain barrier (BBB) and is rapidly distributed to all organs. The identification of the pharmacokinetics of MDHB following its oral administration will contribute to further preclinical and clinical studies of its effects.
Compliance with Ethical Standards
This work was supported by grants from the National Natural Science Foundation Committee of China (grant nos. 81473296, 81173037 and 81202519), the National Program on Key Basic Research Project (973 Program; no. 2011CB707500) and the Guangdong Provincial Department of Science and Technology (grant nos. 2012B050300018 and 2010B030700018).
Conflict of Interest
None of the authors have conflicts of interest to declare.
The animal experiments adhered to the “Jinan University Medical College Animal Use Ordinance” and were approved by the Ethics Committee of the Medical School of Jinan University.
- 9.Bi DL, Wen L, Xiong W, Shen Y. Development of potential therapeutic targets of and approaches to Alzheimer disease. Chin J Pharmacol Toxicol. 2015;29(04):507–36.Google Scholar
- 11.Xu WQ, Gong XJ, Zhou X, Zhao C, Chen HG. Chemiacal constituents and bioactivity of Kalimeris indica. China J Chin Mater Med. 2010;35(23):3172–4.Google Scholar
- 12.Ma L, Li JM, Chen YQ, Li Y, Guo XJ. Determination of 3, 4-dihydroxy methyl benzoate in Hedyotis diffusa Willd by HPLC. LishiZhen Med Mater Med Res. 2009;20(03):528–9.Google Scholar
- 13.Zhang Z, Zhou X, Zhou XW, Xu X, Liao MJ, Yan L, et al. Methyl 3,4-dihydroxybenzoate promotes neurite outgrowth of cortical neurons cultured in vitro. Neural Regen Res. 2012;7(13):971–7.Google Scholar
- 19.Guidance for industry, bioanalytical method validation. US Food and Drug Administration. 2013. https://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm368107.pdf. Accessed 15 Dec 2017.
- 20.Zhong DF, Li G, Liu CX. Guidance on bioanalysis: method validation and analysis of study samples (draft). Drug Eval Res. 2011;34(06):409–15.Google Scholar
- 21.Guidance for non-clinical pharmacokinetics study. China Food and Drug Administration. 2014. http://www.sda.gov.cn/WS01/CL1616/101019.html. Accessed 15 Dec 2017.
- 23.Xu ZY. Studies on pharmacokinetic and metabolic mechanism of Timosaponin B-II. Shanghai: Second Military Medical University; 2013.Google Scholar
- 25.Chen C, Xu L, Zheng QS. Study of the algorithm of elimination half-life time in pharmackinetics. Chin J Clin Pharmacol Ther. 2013;18(08):891–7.Google Scholar
- 26.Wang GJ. Pharmacokinetics. 1st ed. Beijing: Chemical Industry Press; 2005.Google Scholar
- 27.Cao YX. Discussion on apparent distribution volume in pharmacology textbooks. Negative. 2013;4(04):31–2.Google Scholar
- 35.Jin LW, Wei WF, Gao Y. Research progress in penetration mechanism of chemical constituents in chinese materia medica into blood-brain barrier and penetration enhancing methods. Chin Tradit Herb Drugs. 2013;44(15):2183–8.Google Scholar
- 36.Deng QY, Dong J. The research progress of chinese herb and its active ingredient through blood-brain barrier mechanism. Chin J Gerontol. 2011;31(18):3639–41.Google Scholar
- 37.Mikitsh JL, Chacko AM. Pathways for small molecule delivery to the central nervous system across the blood-brain barrier. Perspect Med Chem. 2014;6:11–24.Google Scholar
- 38.Jiang RG, Qi XR. Blood brain barrier model and central nervous system drug transport evaluation. Chin Pharm J. 2012;47(11):880–3.Google Scholar
- 40.Zhang DL, Zhu, Humphreys WG. Drug metabolism in drug design and development- basic concepts and practice, vol. 1. Beijing: People’s Military Medical Press; 2011.Google Scholar
- 41.Agundez JA, Jimenez-Jimenez FJ, Alonso-Navarro H, Garcia-Martin E. Drug and xenobiotic biotransformation in the blood-brain barrier: a neglected issue. Front Cell Neurosci. 2014;8:335.Google Scholar
- 42.Zhang ZQ, Sheng L, Li Y. Drug glucuronidation and disposition in brain. Acta Pharm Sin. 2016;51(11):1674–80.Google Scholar
- 43.Wang XY, Yan KJ, Ma XH, Li W, Chu Y, Guo JH, et al. Simultaneous determination and pharmacokinetic study of protocatechuic aldehyde and its major active metabolite protocatechuic acid in rat plasma by liquid chromatography-tandem mass spectrometry. J Chromatogr Sci. 2016;54(5):697–705.CrossRefGoogle Scholar